|
|
||||||||
Published online before print March 9, 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Divisions of
* Clinical Neurology and
Molecular and Clinical Immunology, University of Nottingham, Nottingham, United Kingdom
1 Correspondence: Division of Clinical Neurology, Queens Medical Centre, Medical School, University of Nottingham, Nottingham NG7 2UH, UK. E-mail: cris.constantinescu{at}nottingham.ac.uk
IL-12 is an immunoregulatory cytokine, which promotes Th1 cell differentiation and is a major inducer of IFN-
. IFN-ß, a Type I IFN used in the treatment of multiple sclerosis, has been shown to significantly increase the expression of the anti-inflammatory cytokine IL-10, a major suppressor of Th1 cytokines. The beneficial immunomodulatory effects of IFN-ß may in part be a result of its ability to suppress IL-12. However, IL-12 and IFN-ß signal via the STAT4 pathway. Our aim was to investigate the relationship between IL-12 and IFN-ß by observing the effect of prior exposure to IL-12 or IFN-ß on the ability of T cells to subsequently respond to the other cytokine. We report that IFN-ß increases IL-12-induced STAT4 phosphorylation and up-regulates IL-12 receptor ß1 and ß2 expression. However, despite this up-regulation, IFN-ß suppressed IL-12-induced IFN-
expression. Our results suggest that this may be a result of the parallel induction of IL-10 by IFN-ß.
Key Words: human signal transduction IFN-gamma interleukin-10
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |